To include your compound in the COVID-19 Resource Center, submit it here.

Empagliflozin: Phase II data

A double-blind, international Phase II trial in 495 Type II diabetics inadequately controlled with metformin showed that all doses of once-daily empagliflozin plus metformin met the primary endpoint of significantly reducing HbA1c from baseline to week 12 vs.

Read the full 381 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers